Literature DB >> 12707268

Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor.

Shiqing Li1, Nicole D Covino, Evan G Stein, Jeffrey H Till, Stevan R Hubbard.   

Abstract

Tyrosine 984 in the juxtamembrane region of the insulin receptor, between the transmembrane helix and the cytoplasmic tyrosine kinase domain, is conserved among all insulin receptor-like proteins from hydra to humans. Crystallographic studies of the tyrosine kinase domain and proximal juxtamembrane region reveal that Tyr-984 interacts with several other conserved residues in the N-terminal lobe of the kinase domain, stabilizing a catalytically nonproductive position of alpha-helix C. Steady-state kinetics measurements on the soluble kinase domain demonstrate that replacement of Tyr-984 with phenylalanine results in a 4-fold increase in kcat in the unphosphorylated (basal state) enzyme. Moreover, mutation of Tyr-984 in the full-length insulin receptor results in significantly elevated receptor phosphorylation levels in cells, both in the absence of insulin and following insulin stimulation. These data demonstrate that Tyr-984 plays an important structural role in maintaining the quiescent, basal state of the insulin receptor. In addition, the structural studies suggest a possible target site for small molecule activators of the insulin receptor, with potential use in the treatment of noninsulin-dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707268     DOI: 10.1074/jbc.M302425200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Classic and contemporary approaches to modeling biochemical reactions.

Authors:  William W Chen; Mario Niepel; Peter K Sorger
Journal:  Genes Dev       Date:  2010-09-01       Impact factor: 11.361

2.  Autoinhibition of the insulin-like growth factor I receptor by the juxtamembrane region.

Authors:  Barbara P Craddock; Christopher Cotter; W Todd Miller
Journal:  FEBS Lett       Date:  2007-06-19       Impact factor: 4.124

3.  Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.

Authors:  Hui-Min Zhang; Xiu Yu; Michael J Greig; Ketan S Gajiwala; Joe C Wu; Wade Diehl; Elizabeth A Lunney; Mark R Emmett; Alan G Marshall
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

4.  The insulin and IGF1 receptor kinase domains are functional dimers in the activated state.

Authors:  M Zulema Cabail; Shiqing Li; Eric Lemmon; Mark E Bowen; Stevan R Hubbard; W Todd Miller
Journal:  Nat Commun       Date:  2015-03-11       Impact factor: 14.919

Review 5.  More than the sum of the parts: Toward full-length receptor tyrosine kinase structures.

Authors:  Devan Diwanji; Tarjani Thaker; Natalia Jura
Journal:  IUBMB Life       Date:  2019-05-02       Impact factor: 3.885

Review 6.  The insulin receptor: both a prototypical and atypical receptor tyrosine kinase.

Authors:  Stevan R Hubbard
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

7.  Cytoskeletal components enhance the autophosphorylation of retinal insulin receptor.

Authors:  Raju V S Rajala; Ammaji Rajala
Journal:  Chem Biol Interact       Date:  2009-03-31       Impact factor: 5.192

8.  Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB.

Authors:  Stephen C Artim; Anatoly Kiyatkin; Mark A Lemmon
Journal:  Biochem J       Date:  2020-10-30       Impact factor: 3.857

Review 9.  Receptor tyrosine kinase activation: From the ligand perspective.

Authors:  Raphael Trenker; Natalia Jura
Journal:  Curr Opin Cell Biol       Date:  2020-02-27       Impact factor: 8.382

10.  A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation.

Authors:  Henry J Tsai; Shan-Yen Chou
Journal:  J Biomed Sci       Date:  2009-07-30       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.